Characteristics | Fuzhou training cohort (355) | Fuzhou internal validation cohort (334) | Harbin external validation cohort (253) | Total cohort (942) |
---|---|---|---|---|
Age | ||||
 ≤50 | 199 (56.1%) | 194 (58.1%) | 136 (53.8%) | 529 (56.2%) |
 >50 | 156 (43.9%) | 140 (41.9%) | 117 (46.2%) | 413 (43.8%) |
Molecular subtype | ||||
 Luminal A | 75 (21.1%) | 59 (17.7%) | 69 (27.3%) | 203 (21.5%) |
 Luminal B | 161 (45.4%) | 145 (43.4%) | 97 (38.3%) | 403 (42.8%) |
 HER2-enriched | 64 (18.0%) | 75 (22.5%) | 48 (19.0%) | 187 (19.9%) |
 Triple negative | 55 (15.5%) | 55 (16.5%) | 39 (15.4%) | 149 (15.8%) |
Tumor size | ||||
 ≤2cm | 147 (41.4%) | 134 (40.1%) | 143 (56.5%) | 424 (45.0%) |
 2–5cm | 187 (52.7%) | 174 (52.1%) | 107 (42.3%) | 468 (49.7%) |
 >5cm | 21 (5.9%) | 26 (7.8%) | 3 (1.2%) | 50 (5.3%) |
Nodal status | ||||
 0 | 180 (50.7%) | 169 (50.6%) | 117 (46.3%) | 466 (49.5%) |
 1–3 | 74 (20.8%) | 81 (24.3%) | 75 (29.6%) | 230 (24.4%) |
 ≥4 | 101 (28.5%) | 84 (25.1%) | 61 (24.1%) | 246 (26.1%) |
Clinical stage | ||||
 I | 96 (27.0%) | 83 (24.9%) | 74 (29.3%) | 253 (26.9%) |
 II | 156 (43.9%) | 161 (48.2%) | 117 (46.2%) | 434 (46.1%) |
 III | 103 (29.1%) | 90 (26.9%) | 62 (24.5%) | 255 (27.0%) |
Histological grade | ||||
 G1 | 56 (15.8%) | 56 (16.8%) | 11 (4.4%) | 123 (13.1%) |
 G2 | 194 (54.6%) | 176 (52.7%) | 202 (79.8%) | 572 (60.7%) |
 G3 | 105 (29.6%) | 102 (30.5%) | 40 (15.8%) | 247 (26.2%) |
ER | ||||
 Negative | 119 (33.5%) | 130 (38.9%) | 87 (34.4%) | 336 (35.7%) |
 Positive | 236 (66.5%) | 204 (61.1%) | 166 (65.6%) | 606 (64.3%) |
PR | ||||
 Negative | 152 (42.8%) | 155 (46.4%) | 108 (42.7%) | 415 (44.1%) |
 Positive | 203 (57.2%) | 179 (53.6%) | 145 (57.3%) | 527 (55.9%) |
HER2 | ||||
 Negative | 243 (68.5%) | 213 (63.8%) | 171 (67.6%) | 627 (66.6%) |
 Positive | 112 (31.5%) | 121 (36.2%) | 82 (32.4%) | 315 (33.4%) |
Chemotherapy | ||||
 No | 28 (7.9%) | 28 (8.4%) | 27 (10.7%) | 83 (8.8%) |
 Yes | 327 (92.1%) | 306 (91.6%) | 226 (89.3%) | 859 (91.2%) |
Endocrine therapy | ||||
 No | 135 (38.0%) | 140 (41.9%) | 133 (52.6%) | 408 (43.3%) |
 Yes | 220 (62.0%) | 194 (58.1%) | 120 (47.4%) | 534 (56.7%) |
Radiation therapy | ||||
 No | 234 (65.9%) | 232 (69.5%) | 195 (77.1%) | 661 (70.2%) |
 Yes | 121 (34.1%) | 102 (30.5%) | 58 (22.9%) | 281 (29.8%) |
Targeted therapy | ||||
 No | 331 (93.2%) | 311 (93.1%) | 228 (90.1%) | 870 (92.4%) |
 Yes | 24 (6.8%) | 23 (6.9%) | 25 (9.9%) | 72 (7.6%) |